BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same

Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the...

Full description

Saved in:
Bibliographic Details
Main Authors Sullivan, Gerard M, Welch, Dennie S, Judd, Andrew S, Bennett, Nathan B, Cullen, Steve C, Kunzer, Aaron R, Doherty, George, Wang, Xilu, Tao, Zhi-Fu, Song, Xiaohong, Wendt, Michael D, Frey, Robin R, Boghaert, Erwin R, Haight, Anthony R, Ackler, Scott L, Shen, Xiaoqiang, Souers, Andrew J
Format Patent
LanguageEnglish
Published 30.07.2020
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
Bibliography:Application Number: US201916675784